Acclaro Medical
United States
- Smithfield, RI
- 30/05/2025
- Series B
- $23,000,000
Founded in 2018 by world-class industry experts and top physicians in the nation, Acclaro Corporation is a US-based, VC-backed, fast-growing medical device company committed to innovating and developing game-changing solutions to address today’s most challenging unmet needs in the global medical aesthetic, ophthalmic and surgical markets.
Acclaro Medical’s flagship product, UltraClear® is the world’s first and only cold, ablative fiber laser platform, a breakthrough painless anti-aging solution and the first ablative laser not requiring topical numbing for most treatments. Powered by the revolutionary 3DMIRACL® and 3DIntelliPulse™ technologies, UltraClear® is a high-speed, all-skin-type and all-in-one platform with unparalleled energy control capabilities, offering a full range of skin rejuvenation outcomes from true painless and zero-downtime anti-aging lunchtime treatments to most advanced collagen remodeling with superior results, 15-min avg. treatment time and the utmost patient safety and comfort.
- Industry Medical Device
- Website https://ultraclearlaser.com/
- LinkedIn https://www.linkedin.com/company/acclaromedical/
Arycs Technologies | $24,000,000 | (Mar 13, 2026)
Ezra(2) | $8,000,000 | (Mar 13, 2026)
Freestyle | $10,000,000 | (Mar 13, 2026)
Mantis Space | $10,000,000 | (Mar 13, 2026)
Monteris Medical | $28,000,000 | (Mar 13, 2026)
Gumloop | $50,000,000 | (Mar 13, 2026)
Combat Medical Ltd | $3,472,639 | (Mar 13, 2026)
Qurrent | $15,000,000 | (Mar 13, 2026)
Waiv, formerly Owkin Dx | $33,000,000 | (Mar 13, 2026)
Carefam | $14,500,000 | (Mar 13, 2026)
Option Circle | $3,000,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)